To overcome the limitations of previous therapeutics, we created Sigyn Therapy™, a blood purification technology that extracts pathogen sources of life-threatening inflammation in concert with the broad-spectrum elimination of inflammatory mediators that fuel sepsis, the #1 cause of hospital deaths worldwide.
Our CompanyIn the United States, the annual financial burden to treat sepsis alone is estimated to be $24 billion.
Since December of 2020, a series of invitro studies have validated the ability of Sigyn Therapy to extract a broad-spectrum of viruses, bacterial toxins, hepatic toxins, and inflammatory mediators form human blood plasma.
About Sigyn TherapyPrior to establishing Sigyn Therapeutics, our co-founders played instrumental roles in the development of three different technologies that the United States Food and Drug Administration (FDA) has permitted for use to treat COVID-19 infected individuals.
Stay informed and receive company updates straight to your inbox.
